National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Zykadia® is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.

Rapid Review

Commenced Completed Outcome
29/05/2015 22/07/2015 Full Pharmacoeconomic Evaluation Recommended at the submitted price.

The HSE has approved reimbursement following confidential price negotiations.